Dr. Clamon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Hawkins Dr
Iowa City, IA 52242Phone+1 319-356-1932Fax+1 319-353-8377
Education & Training
University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1976 - 1977
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1974 - 1976- Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 1971 - 1972
- Washington University in St. Louis School of MedicineClass of 1971
Certifications & Licensure
IA State Medical License 1976 - 2024
MO State Medical License 1974 - 2016
WI State Medical License 1978 - 2007- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2 Start of enrollment: 2000 Feb 01
- Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer Start of enrollment: 2000 Dec 18
Publications & Presentations
PubMed
- 1262 citationsMeta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung CancerAnne Auperin, Cécile Le Péchoux, Estelle Rolland, Walter J. Curran, Kiyoyuki Furuse
Journal of Clinical Oncology. 2010-05-01 - 29 citationsHigh-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234N. J. Vogelzang, James E. Herndon, Antonius A. Miller, Gary M. Strauss, Gerald H. Clamon
Annals of Oncology. 1999-05-01 - 22 citationsPhase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acid.Gerald H. Clamon, Guy G. Chabot, Frederick Valeriote, Enrique Davilla, Charles Vogel
Cancer Research. 1985-04-01
Grant Support
- Calgb 60301: Sorafenib For Solid Tumors And Hematologic MalignanciesNational Center For Research Resources2006
- University Of Iowa Calgb Institutional GrantNational Cancer Institute2004–2006
- Data &Safety MonitoringNational Cancer Institute2005
- Calgb 60101 Phase I Study Of OSI-774 For Solid TumorsNational Center For Research Resources2004–2005
- Calgb Institutional GrantNational Cancer Institute2003
- Univ Of Iowa Calgb Institutional GrantNational Cancer Institute1998–2002
- Cancer And Leukemia Group BNational Cancer Institute1993–1997
- University Of Iowa Institutional Calgb GrantNational Cancer Institute1988–1992
- Southeastern Cancer Study GroupNational Cancer Institute1986
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
